87 KB11 KB192920262004Černelč, Peterstr. I-35-I-37ISSN:1318-0347COBISSID_HOST:17679321URN:URN:NBN:SI:doc-RKYYTN74slSlovensko zdravniško društvoZdravniški vestnikCladribineDrug TherapyKladribinLeukemia, Hairy CellLevkemija z dlakastimi celicamiTreatment OutcomeZdravljenje, izidNaše izkušnje zdravljenja bolnikov z dlakastocelično levkemijo s kladribinom| Follow-up of patients with hairy cell leukemia after treatment with cladribine|Background. The long-term outcome in 16 patients with hairy cell leukemia (HCL) treated with cladribine between 1995 and 2003 is reported. Patients and methods. Cladribine was administered to 13 patients in a dose 0.1 mg/kg/day for 7 days, and the same daily dose was applied once a week for 6 weeks in 3 patients. Their mean age was 57 years (range 32-67) and the male to female ratio 8:1. Four patients had also received a prior therapy with interferon andone was splenectomised. Results. Complete remission (CR) was achieved in 12(75%) patients and partial remission (PR) in 4 (25%) of cases. With a followup of 9 years in 12 patients CR lasted between 18 and 88 months (mean 68), 3 (25%) of them relapsed after 54-80 months (mean 71) while 4 patients with PR progressed after 40 to 76 months (mean 63). Six patients had an infection prior to or during the treatnaent. Conciusions. In HCL patients cladribine treatment yields high percentage of CR and durable response, tolerable toxicity and prolonged survivalIzhodišča. Uspešnost zdravljenja s kladribinom ocenjujejmo pri 16 bolnikih z dlakastocelično levkemijo (DCL) v obdobju od leta 1995 do 2003. Bolniki in metode. Srednja starost bolnikov z DCL je bila 57 let (32-67 let), odnos med moškimi in ženskami je bil 8:1. 4 bolnike smo pred tem zdravili z interferonomalfa, enega pa s splenektomijo. 13 bolnikov je prejemalo kladribin0,1 mg/kg/ na dan 7 dni, 3 bolniki so dobivali enak dnevni odmerek enkrat na teden 6 tednov. Rezultati. Popolno remisijo bolezni (PR) smo doseglipri 12 (75%) bolnikih, delno remisijo (DR) pa pri 4 (25%) bolnikih. Po 9 letih ugotavljamo da so bili bolniki v PR od 18 do 88 mesecev (mediana 68), bolezen se je ponovila pri 3 (25% bolnikih, ki so bili v PR od 54-80 mesecev (mediana 71), in pri vseh 4 bolnikih ki so bili v DR od 40 do 76 mesecev (mediana 63). Šest bolnikov je imelo okužbo pred ali med zdravljenjem s kladribinom. Zaključki. Po zdravljenju s kladribinom dosežemo velik delež dolgih PR. Okužbe so glavni zaplet zdravljenja, zato profilaktično dajemo protibakterijska in protiglivična zdravilaTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo